近畿大学　 呼吸器・
アレルギー内科学教室

1.        Oguma T, Ishiguro T, Matsumoto H, Asano K, et al. Clinical characteristics of allergic bronchopulmonary mycosis caused by Schizophyllum commune. Clin Transl Allergy. 2024;14:e12327
2.        Sano A, Kozuka T, Watatani N, Kunita Y, Kawabata Y, Gose K, Shirahase K, Yoshikawa K, Yamazaki R, Nishikawa Y, Omori T, Osamu N, Takashi I, Sano H, Haraguchi R, Tohda Y, Matsumoto H. Role of bronchial hyperresponsiveness in Patients with obstructive sleep apnea with asthma-like symptoms. Allergol Int. 2024;73:231-5
3. 　　　Nishi K, Nagasaki T, Matsumoto H, et al. Increased blood eosinophils and airflow obstruction as new-onset asthma predictors in the elderly: The Nagahama study. Allergol Int. 2024;73:236-42
4.          Mizusawa H, Matsumoto H, Nishiyama O, Shiraishi M, Higashimoto Y, et al. Evaluation of patients with chronic obstructive pulmonary disease by maximal inspiratory pressure and diaphragmatic excursion with ultrasound sonography. Respir Investig 2024;62:234-239
   
5.         Hayashi Y, Tanabe N, Matsumoto H, et al. Associations of fractional exhaled nitric oxide with airway dimention and mucus plugs on ultra hight resolution computed tomography in former smokers and nonsmokers with asthma. Allergol Int 2024; 73:397-405
6.       Yamazaki R, Nishiyama O, Yoshikawa K, Gose K, Oomori T, Nishikawa Y, Sano A, Matsumoto H. Incidence, etiology, and outcome of hospital-acquired pneumonia in patients with acute exacerbation of fibrotic idiopathic interstitial pneumonia. Respir Investig 2024;62:488-493
7.      Ishiura Y, Fujimura M, Matsumoto H, et al. Prevalence and causes of chronic cough in Japan. Respir Investig 2024;62:442-448
8.       Tanabe N, Kumamaru H, Nishiyama O, et al. Pulmonary hypertension with interstitial pneumonia: Initial treatment effectiveness and severity in a Japan Registry. JACC Asia  2024;4:404-417
9. 　　Yamazaki R, Nishiyama O, Yoshikawa K, Gose K, Oomori T, Nishikawa Y, Sano A, Matumoto H. Incidence, etiology, and outcome of hospital-acquired pneumonia in patients with acute exacerbation of fibrotic idiopathic interstitial pneumonia. Respir Investig 2024;62:488-493
10.       Shiraishi M, Higashimoto Y, Nisiyama O, Yamazaki R, Matsumoto H, et al. Improvement of diaphragmatic excursion in the supine position in a patient with idiopathic pleuroparenchymal fibroelastosis: A case report. Respir Med Case Rep 2024;51:102078
11.        Yoshikawa K, Nishiyama O, Yamazaki R, Kunita Y, Nishikawa Y, Sano A, Matsumoto,H.Selexipag for patients with pulmonary hyperttension associated with lung disease:A preliminary study. Respir Investig 2024;62:850-855
12.         Sakao S, Kondoh Y, Nishiyama O, et al.  Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease. Respir Investig 2024;62:980-986

1. 　　西山　理. 肺動脈性肺高血圧症.今日の治療指針.2024;326-328.医学書院
2. 　　西山　理. 肺疾患にも肺高血圧症は隠れています　かかりつけ医に必要な肺高血圧症の新知識―各専門医からの提言―.大阪府内科医会会誌.2024;32(2)127-132.大阪府内科医会
3.       松本　久子. 咳喘息とアトピー咳嗽. 今日の治療指針.2024；839-841、医学書院
4. 　　松本　久子. 慢性咳嗽診療の基本と注意点. BIO Clinica　慢性咳嗽のすべて.2024;4-5,北隆館 
5. 　　松本　久子. 慢性咳嗽（咳喘息). 呼吸器内科学レビュー.2024；137-142,総合医学社
6.       松本　久子. 好酸球性気管支拡張症. "気管支拡張症　温故知新　注目され始めた一大カテゴリー". 呼吸器ジャーナル.2024；72：2-9、医学書院
7.       西山　理. 肺高血圧症の診断からリハビリテーションまで.呼吸器ケア・リハビリテーション学会誌.2024;32:180-184,日本呼吸ケア・リハビリテーション学会
8. 　　松本　久子. 重症喘息の長期管理. "気管支喘息　古くて新しい疾患" Medical Practice 2024; 41:11-9, 文光堂
9.       西山　理. 吸入プロスタサイクリン誘導体製剤トレプロスチニル(トレプロスト®吸入液1.74mg)の特徴及び間質性肺疾患に伴う肺高血圧症における臨床成績. 診療と新薬. 2024；61：651-662 ,医事出版社

1. 　　    Yamazaki R, Nishiyama O, Matsumoto H, et al. Prognostic value of the qSOFA in patients with acute exacerbation of idiopathic pulmonary fibrosis.Respir Investig.2023;61:339-346
2.       Kataoka K, Nishiyama O, Ogura T,et al. Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial. Thorax.2023;78:784-791
3.       Nishi K, Yoshimura C, Morita K, Nagasaki T, Matsumoto H, Nishizaka H,　et al. Effectiveness of bronchial thermoplasty in patients with asthma exhibiting overweight/obesity and low quality of life. World Allergy Organ J. 2023;16:100756
4.       Nomura M, Matsumoto H, et al. Importance of mucus burden and mucociliary impairment in asthma. J Allergy Clin Immunol. 2023;151:1410-1411
5.       Tashima N, Matsumoto H, Nagasaki T, Tabara Y, et al. Evaluation of elevated plasma fatty acids as relevant factors for adult-onset asthma: The Nagahama Study. Allergol Int 2024; 73: 65-70　　
6.       Pfeffer P , Ali N, Iwanaga T, et al. Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023;78:1934-1948
7. 　　Shiraishi M, Higashimoto Y, Sugiya R, Matsumoto H, et al. Diaphragm dome height in chest X-ray as a predictor of dynamic lung hyperinflation in COPD. ERJ Open Res 2023; 9: 00079-2023
8. 　　Shiraishi M, Higashimoto Y, Sugiya R, Nishiyama O, et al. Sternocleidomastoid muscle thickness crrelates with exercise tolerance in patients with COPD. Respiration 2023;102:64-73
9.       Kogo M, Sato S, Muro S, Matsumoto H, et al. Longitudinal Changes and Association of Respiratory Symptoms with Preserved Ratio Impaired Spirometry (PRISm): The Nagahama Study. Ann Am Thorac Soc 2023; 20:1578-86
10.      Maetani T, Tanabe N, Sato A, Shiraishi Y, Sakamoto R, Ogawa E, Sakai H, Matsumoto H, et al. Association between blood eosinophil count and small airway eosinophils in smokers with and without chronic obstructive pulmonary disease
     ERJ Open Res 2023; 9: 00235-2023
11.       Terada S, Matsumoto H, Nagasaki T, et al. Association of lower plasma citric acid with prolonged cough: the Nagahama study. Sci Rep 2023; 13: 13921
12.       Morimoto C, Matsumoto H, Nagasaki T, et al.  Sputum microbiota and inflammatory subtypes in asthma, COPD, and its overlap. J Allergy Clin Immunol Global 2023; 3: 100194
13.       Hanada S, Muraki M, Kawabata Y, Yoshikawa K, Yamagata T, Nagasaki T, Ohara Y, Oiso N, Matsumoto H, Tohda Y. Significance of Self-Injectable Biologics in Japanese Patients with Severe Allergic Diseases: Focusing on Pen-Type Devices and Copayment 2023;17:2847-2853
14.       Senda S, Fujita E, Aoki T, et al. The utility of the Self Grow-up Egogram（SGE）for stress management in patients with respiratory diseases.職業・環境アレルギー誌.2023;30(2):61-68
15.        Fujita E, Kakishita K, Yamazaki R, Matsumoto H, et al. Clinical Effects of Music Therapy on. Electroencephalographs in Dementia after Recovery from Pneumonia: A Case Report. J. Clin. Physiol.2023;53:13-18
16.          Maetani T, Tanabe N, Matsumoto H, et al. Association between blood eosinophil count and small airway eosinophils in smokers with and withaut COPD.ERJ Open Res. 2023;9(5)235
          

1.       松本久子.咳喘息とはどのような疾患ですか？また,呼吸機能検査やその他の臨床検査でどのような注意が必要ですか？.臨床検査.2023；67：265-267
2. 　　松本久子.医学と医療の最前線.重症喘息に対する生物学的製剤の使用.日本内科学会雑誌.2023；112：693-699
3. 　　松本久子.喘息,COPDと気管支拡張症.呼吸器内科.2023；43：26-32
4. 　　松本久子.気管支喘息－成人.臨床と研究.2023;100:20-25
5.       松本久子.気管支拡張症.喘息・COPDと気道疾患　包括診療マニュアル.永田真編.2023：240－248.中外医学社
6. 　　松本久子.鎮咳薬.呼吸器疾患 最新の治療.弦間昭彦/西岡安彦/矢寺和博編.2023-2024 81-83.南江堂
7.       佐野博幸.成人喘息―実地臨床に求められる診断とモニタリング.アレルギーの臨床.2023;43:13-16.北隆館
8.        松本久子.咳喘息.アロスエルゴン 特集「咳の診断」.2023;3(1).クリニコ出版
9. 　　  山﨑　亮,松本久子.肺血管炎.呼吸器ジャーナル　呼吸器画像診断　疾患理解が深まる読解のコツ. 2023;71(3)426-432,医学書院
10. 　　　長崎忠雄,松本久子.いつ生物学的製剤を用いるか.CURRENT THERAPY　喘息,COPD,喘息・COPDオーバーラップ症候群の病態生理.2023;41(10)31-36.ライフメディコム
11. 　　　野村奈都子,松本久子.気管支喘息と気管支拡張症－気管支拡張症合併難治性喘息の実態調査-.呼吸器内科.2023;43(4):404-410.科学評論社
12. 　　　松本久子.非呼吸器疾患における咳嗽のメカニズムと対応１）胃食道逆流症.呼吸器内科.2023;44(1):30-34.科学評論社
13. 　　　長崎忠雄, 松本久子. 重症喘息におけるテゼペルマブ. アロスエルゴン. 2023; 3 (3). クリニコ出版

1.          Masuda S, Nagao M, Usui S, Tohda Y, et al. Development of allergic rhinitis in early life: A prospective cohort study in high-risk infants. Pediatr Allergy Immunol.2022;33(2)
   
2.             Tajiri T, Matsumoto H, et al. Pathophysiological relevance of sputum MUC5AC and MUC5B levels in patients with mild asthma. Allergol Int.2022;71(2):193-199
   
3.           Okoshi K, Hida K, Kinoshita K, Matsumoto H, et al. Measurement of particulate matter 2.5 in surgical smoke and its health hazards. Surg Today.2022;1-7
4.             Nagasaki T, Tabuchi T, Matsumoto H, Horimukai K. Age-specific associations of early daycare, older siblings, severe airway infection, and preterm birth with subsequent atopic diseases. Pediatr Allergy Immunol.2022;33(4):e13771
5.         Yamazaki R, Nishiyama O, Yoshikawa K, et al. Outcome of patients who were incidentally diagnosed with idiopathic pulmonary fibrosis: How early in the disease should we identify patients. Respi Med.2022; 106933
6. 　　　　Morimoto C, Matsumoto H, Ito I, et al.Roles of Staphylococcus aureus and sensitization to staphylococcal enterotoxin in bronchiectasis.Respir Investig.2022;60(6)  
7.           Shiraishi M, Higashimoto Y, Nishiyama O,et al. Sternocleidomastoid Muscle Thickness Correlates with Exercise Tolerance in Patients with COPD. Respiration.2022;22:1-10    
8.          Nomura N, Matsumoto H, Yokoyama A,et al. Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes. Respir Res.2022;23:365
9.         Kogo M, Sato S, Matsumoto H,et al. Development of airflow limitation,dyspnoea, and both in the general population: the Nagahama study. Sci Rep. 2022;12:20060 
10. 　　　杉谷竜司, 西山理，松本久子,他.　健常若年者における胸鎖乳突筋のエコー評価の信頼性の検討. 日本呼吸ケア・リハビリテーション学会誌. 2022;31(1):129-134
11.          綿谷奈々瀬,西山理,國田裕貴,他.国内での牛の生肝喫食禁止後に感染した無症状肺トキソカラ症の1例.感染症学雑誌.2022;96(3):101-105   

1. 　　　Matsumoto H. Bronchiectasis in severe asthma and asthmatic components in bronchiectasis. Respir Investig.2022;60(2):187-196
2.           松本久子,喘息・COPD の増悪に対する治療・管理のポイント.近畿大医誌（Med J Kindai Univ）.2022;47(1-2):27-36
3. 　　　松本久子. 成人喘息の基本知識から最新情報まで:病態生理[専門医のためのアレルギー学講座].アレルギー.2022;71(9): 1065-1071
4. 　　　松本久子. 経口ステロイド治療再考[最新ガイドラインと今後の喘息診療の展望].呼吸器内科.2022;42(3): 291-298
5. 　　　西山理.呼吸器疾患に合併した肺高血圧症の現状と今後の展望について.日本医事新法.2022;5142:50
6.        岩永賢司,竹山宜典,東田有智. COPDと喘息の境界領域:Asthma-COPD overlap(ACO)診断と治療.日本臨牀 特集:COPDと気管支喘息,その周辺疾患.2022;80(増刊6):45-50
7.           松本久子.アレルギー性気道炎症から考える喘息病態と治療.日本臨牀 特集:COPDと気管支喘息,その周辺疾患.2022;80(増刊6):144-149
8.          松本久子.気管支拡張症[私の治療].日本医事新報.2022;5110:38
9.          松本久子.気管支喘息[原因・併存疾患ごとの気管支拡張症の病態].気管支拡張症Up To Date.長谷川直樹/森本耕三編.2022 南江堂
10.          松本久子.黄色ブドウ球菌エンテロトキシン [アレルギー用語解説シリーズ]. アレルギー.2022;71(4):336-337
11. 　　　松本久子.難治性慢性咳嗽治療の現状：難治病態の概要.Progress in Medicine.2022；42：567-572.
12.          松本久子.気管支拡張症 [呼吸器疾患].今日の治療指針.2022 医学書院 
13.          佐野博幸.過敏性肺炎 [呼吸器疾患].今日の治療指針.2022 医学書院
14.         松本久子.慢性咳嗽(咳喘息)[アレルギー肺疾患].呼吸器内科学レビュー2022-’23. 弦間昭彦監修. 総合医学社

1                Yamazaki R, Nishiyama O, Yoshikawa K, et al. HFpEF without elevated right ventricular systolic pressure is a favorable prognostic indicator in patients with IPF requiring hospitalization for heart failure. PLoS One. 2021; 16: e0245778.

2                Yamazaki R, Nishiyama O, Yoshikawa K, et al. Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis. Respir Investig. 2021; 59: 408-13.

3                Yamazaki R, Nishiyama O, Yoshikawa K, et al. Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in patients with idiopathic pulmonary fibrosis. Sci Rep. 2021; 11: 3880.

4                Yamazaki R, Nishiyama O, Saeki S, et al. Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation. Sci Rep. 2021; 11: 5782.

5                Yamazaki R, Nishiyama O, Gose K, et al. Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience. BMC Pulm Med. 2021; 21: 5.

6                Sunadome H, Matsumoto H, Tohda Y, et al. Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort. Allergol Int. 2021; 70: 252-4.

7                Sugiya R, Higashimoto Y, Shiraishi M, et al. Decreased Tongue Strength is Related to Skeletal Muscle Mass in COPD Patients. Dysphagia. 2021.

8                Nishiyama O, Shimizu S, Haratani K, et al. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Pulm Med. 2021; 21: 155.

9                Muraki M, Kunita Y, Shirahase K, et al. A randomized controlled trial of long-acting muscarinic antagonist and long-acting beta2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2021; 21: 26.

10              Iwanaga T, Tanaka H, Hozawa S, et al. A questionnaire validated using local treatment guidelines may better predict future asthma risk: MARGIN study. Respir Investig. 2021.

11              Higashimoto Y, Shiraishi M, Sugiya R, et al. Effect of Pulmonary Rehabilitation on Erector Spinae Muscles in Individuals With COPD. Respir Care. 2021.

12              Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021.

13              Tashima N, Matsumoto H, Nomura N, et al. Airway clearance ameliorated the control of diffuse panbronchiolitis accompanied by asthma and leukocytoclastic vasculitis. Allergol Int. 2021; 70: 131-3.

14              Tanabe N, Sato S, Oguma T, et al. Influence of Asthma Onset on Airway Dimensions on Ultra-high-resolution Computed Tomography in Chronic Obstructive Pulmonary Disease. J Thorac Imaging. 2021; 36: 224-30.

15              Tanabe N, Matsumoto H, Hamada S, et al. Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia. Allergol Int. 2021; 70: 274-6.

16              Sunadome H, Sato S, Matsumoto H, et al. Similar distribution of peripheral blood eosinophil counts in European and East Asian populations from investigations of large-scale general population studies: the Nagahama Study. Eur Respir J. 2021; 57.

17              Shirata M, Ito I, Tanabe N, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus isolation from serially collected sputum samples of patients hospitalized with pneumonia. J Infect Chemother. 2021.

18              Sato R, Handa T, Matsumoto H, et al. Antitussive effect of a chest band in patients with interstitial lung disease: preliminary results from a pre-post intervention study. Int Med. 2021; in press.

19              Oi I, Ito I, Hirabayashi M, et al. Pneumonia caused by severe acute respiratory syndrome coronavirus 2 and influenza virus: A multicenter comparative study. Open Forum Inf Dis. 2021;8(7):ofab282.

20              Niwamoto T, Handa T, Matsui S, et al. Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis. Mod Rheumatol. 2021; 31: 235-40.

21              Nagase H, et al. The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. Respir Investig. 2021; 59(5):679-682.

22              Morimoto C, Matsumoto H, Nagasaki T, et al. Gastroesophageal reflux disease is a risk factor for sputum production in the general population: the Nagahama study. Respir Res. 2021; 22: 6.

23              Matsunaga K, Kuwahira I, Hanaoka M, et al. An official JRS statement: The principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice. Respir Investig. 2021; 59: 34-52.

24              Kitazawa H, Hizawa N, Nishimura Y, et al. The impact of the COVID-19 pandemic on asthma treatment in Japan: Perspectives based on doctors' views. Respir Investig. 2021.

25              Kogo M, Matsumoto H, Tanabe N et al. The importance of central airway dilatation in patients with bronchiolitis obliterans. ERJ Open Res 2021 in press. ERJ Open Res. 2021; 7(4):00123.
26              Matsuhira T, Nishiyama O, Chiba Y, et al. Comprehensive analysis of cytokines in bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis: a cross-sectional study. Acta Med Kindai Univ. 2021; 46:1-7
27              Nishiyama O, Kataoka K, Ando M, et al. Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis. ERJ Open Res. 2021;7(3):00321
28              Tanabe N, Kumamaru H, Tamura Y, et al. Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circulation Journal. 2021;85(4):333-342
29              白波瀬 賢,西山 理,大森 隆,他.アスベスト肺の経過中に発症した多発血管炎性肉芽腫症の1例.日呼吸誌, 2021;10(2):178-182
30              白石 匡,東本 有司,杉谷 竜司,他.横隔膜動態からみた吸気筋トレーニングの適正負荷圧の検討.日本呼吸ケア・リハビリテーション学会誌.2021;29(3):453-459
31              岡島 聡,前田 和成,東本 有司,他. 高齢呼吸器疾患患者の呼吸ケアー認知機能障害に対する対応―.日本呼吸ケア・リハビリテーション学会誌2021;29(3):263-368.
32              Matsuhira T, Nishiyama O, Tabata Y, et al. The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages. Biochem Biophys Rep.2021;28:101118.
33              Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. 2021; Respir Investig.2021;59(6):709-740.
34              Shiraishi M, Higashimoto Y, Sugiya R, Diaphragmatic excursion is correlated with the improvement in exercise tolerance after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.2021; Respir Res.22;22(1):271
35              Saeki S, Nishiyama O,Yamazaki R, et al. Effect of antifibrotic agents on survival in idiopathic pulmonary fibrosis patients according to forced vital capacity: a real-world retrospective cohort study in Japan.Acta Med Kindai Univ.2021;-46(2): 57-64
36              松本 久子.重症喘息の病態解明と個別化治療への展開.近畿大医誌.2021;46(3-4):63-71
37              Tohda Y, Matsumoto H, Miyata M, et al. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. Journal of Asthma.2021;8:1-12

 42            西山理.肺高血圧症･右心不全への対応[慢性呼吸不全の診断と治療へのアプローチ]. 医学書院 呼吸器レジデントマニュアル第6版.2021;456-460

 43            西山理.第10章アレルギー.医学書院 THE 総合内科ドリル:WEB版付.2021;313-318

1                Yamazaki R, Nishiyama O, Saeki S, et al. Characteristics of patients with chronic idiopathic interstitial pneumonia undergoing repeated respiratory-related hospitalizations: A retrospective cohort study. PLoS One. 2020; 15: e0232212.

2                Tohda Y, Nakamura Y, Fujisawa T, et al. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020; 69: 578-87.

3                Tanaka A, Tohda Y, Okamiya K, et al. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma. J Allergy Clin Immunol Pract. 2020; 8: 710-20 e14.

4                Shiraishi M, Higashimoto Y, Sugiya R, et al. Diaphragmatic excursion correlates with exercise capacity and dynamic hyperinflation in COPD patients. ERJ Open Res. 2020; 6.

5               Sano A, Sano H, Iwanaga T, et al. Functional role of phosphatidylcholine-specific phospholipase C in regulating leukotriene synthesis and degranulation in human eosinophils. Eur J Pharmacol. 2020; 884: 173353.

6                Nishikawa Y, Nishiyama O, Shimizu S, et al. Wandering pulmonary shadows coinciding with pericardial and pleural effusions. Thorax. 2020; 75: 817-8.

7                Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020; 69: 519-48.

8                Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020; 69: 53-60.

9              Matsunaga K, Adachi M, Nagase H, et al. Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med. 2020; 30: 35.

10            Matsuhira T, Nishiyama O, Tabata Y, et al. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. Eur J Pharmacol. 2020; 885: 173508.

11              Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med. 2020; 201: 1110-9.

12              Iwanaga T, Tohda Y. [the Jrs Guidelines 2019 for the Management of Refractory Asthma]. Arerugi. 2020; 69: 8-12.

13              Higashimoto Y, Sano A, Nishiyama O, et al. Prefrontal cortex activation is associated with dyspnea during methacholine bronchial provocation tests in patients with bronchial asthma. Allergol Int. 2020; 69: 453-4.

14              Higashimoto Y, Ando M, Sano A, et al. Effect of pulmonary rehabilitation programs including lower limb endurance training on dyspnea in stable COPD: A systematic review and meta-analysis. Respir Investig. 2020; 58: 355-66.

15              FitzGerald JM, Tran TN, Alacqua M, et al. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020; 20: 212.

16              Castro M, Rabe KF, Corren J, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. 2020; 6.

17              Asano K, Sagara H, Ichinose M, et al. A Phase 2a Study of DP2 Antagonist GB001 for Asthma. J Allergy Clin Immunol Pract. 2020; 8: 1275-83 e1.
18              杉谷 竜司,西山 理,白石 匡,他.横隔神経麻痺を合併した小児に対し吸気筋トレーニングが有効であった1例.日本呼吸ケア・リハビリテーション学会誌2020;28(3):484-487